Biomarin Pharmaceutical (BMRN) EBT Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) EBT Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
EBT Growth (1y) (Qtr) |
| 1 |
Alterity Therapeutics |
925,601.88 Bn |
925,601.85 Bn |
- |
- |
| 2 |
Belite Bio |
58,560.00 Bn |
58,560.00 Bn |
- |
-88.68% |
| 3 |
Quantum Biopharma |
17,284.41 Bn |
17,284.40 Bn |
- |
13.34% |
| 4 |
Legend Biotech |
2,809.00 Bn |
2,808.71 Bn |
242.10 Mn |
-51.60% |
| 5 |
Evaxion A |
1,334.43 Bn |
1,334.42 Bn |
- |
-79.57% |
| 6 |
Akari Therapeutics |
1,312.27 Bn |
1,312.26 Bn |
- |
-313.33% |
| 7 |
Psyence Biomedical |
212.16 Bn |
212.16 Bn |
- |
-230.18% |
| 8 |
Vertex Pharmaceuticals |
114.83 Bn |
107.58 Bn |
2.59 Bn |
71.54% |
| 9 |
Abivax |
91.96 Bn |
91.96 Bn |
- |
- |
| 10 |
Biomarin Pharmaceutical |
10.52 Bn |
8.29 Bn |
571.21 Mn |
-40.69% |
| Date | Value |
|---|
| Mar 31, 2026 |
-40.69% |
| Dec 31, 2025 |
-116.01% |
| Sep 30, 2025 |
-119.58% |
| Jun 30, 2025 |
125.43% |
| Mar 31, 2025 |
125.58% |
| Dec 31, 2024 |
777.73% |
| Sep 30, 2024 |
222.64% |
| Jun 30, 2024 |
86.61% |
| Mar 31, 2024 |
85.96% |
| Dec 31, 2023 |
210.08% |
| Sep 30, 2023 |
2,288.50% |
| Jun 30, 2023 |
103.18% |
| Mar 31, 2023 |
-57.70% |
| Dec 31, 2022 |
73.63% |
| Sep 30, 2022 |
95.88% |
| Jun 30, 2022 |
146.19% |
| Mar 31, 2022 |
477.70% |
| Dec 31, 2021 |
-42.07% |
| Sep 30, 2021 |
24.59% |
| Jun 30, 2021 |
133.49% |
